Introduction: What they say:
The 1989 Nobel prize winner in Chemistry, Prof. Thomas R. Cech from the BioFrontiers Institute, USA has published a research paper in the 13 December 2012 Nature (492(7428):285-9; and I.F: >42) stating that “The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity.” This study provides mechanistic insights into how TPP1 regulates telomerase function.
What we say:
In connection with this finding, Dr Boominathan, Founder Director-cum-chief scientist of GBMD, reports that: Anti-telomerase cancer therapy: MiRNA-362 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and inhibits cancer progression via down-regulation of its target gene
Given that: (1) over 90% human tumors overexpress immortality gene telomerase; (2) cancer causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) a way to inhibit telomerase activity in human tumors, to increase the efficacy of anticancer therapy; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; (iv) a way to effectively treat cancers that are resistant to anti-cancer drugs; and (v) a way to effectively treat and eradicate metastatic progression of cancer.
From Research Findings to Therapeutic opportunity:
This study suggests that MiRNA-362, by decreasing the expression of its target gene, it may suppress the expression of Tripeptidyl Peptidase 1 (TPP1). Remarkably, over 90% of the human tumors overexpress the cellular immortality gene telomerase, suggesting that inhibition of its activity may increase the efficacy of anticancer therapy.
Taken together, pharmacological formulations encompassing “MiRNA-362 or its activators or MiR-362 in combination with other anti-cancer drugs“ may be used to treat human cancers that specifically overexpress the cellular immortality gene telomerase.
Details of the Research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed information: How MiRNA-362 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and telomerase
For purchase and payment details, you may reach us at email@example.com
# Research cooperation
Citation: Boominathan, L., Anti-telomerase cancer therapy: MiRNA-362 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and inhibits cancer progression via down-regulation of its target gene, 9/December/2016, 6.18 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org